• 180+

    The UK’s most active investor in UK university spin-outs

  • £500M

    Over £500m raised; invested into over 180 companies

  • £150M

    Cash returned to investors via exits

  • £1.1Bn

    Part of FTSE 250 sector specialist group with £1.1bn net assets

About Parkwalk

Parkwalk is one of the UK’s leading growth fund managers backing world-changing technologies emerging out of UK universities and research institutions with the aim of delivering world-class returns.

Performance

We back high potential, hard science technology companies that aim to shape the future by commercialising innovation in sectors of strategic importance to UK Plc, such as AI, big data, life science, materials, cleantech, future of mobility, medtech and quantum computing.

Learn More

Parkwalk Open Funds

Parkwalk offer early-stage investment funds, investing in high-growth, knowledge intensive companies spun out of the UK’s world-leading universities and providing tax benefits under the Enterprise Investment Scheme.

Opportunities EIS Fund

Our evergreen EIS Fund, investing in EIS-qualifying hard science and deep tech companies spun out of universities across the UK.
Learn More

University of Cambridge Enterprise Fund X

Our UCEF X invests in high-growth, IP-rich technologies founded at the University of Cambridge.
Learn More

Parkwalk Knowledge Intensive EIS Fund IV

The Parkwalk Knowledge Intensive EIS Funds mirror the investment strategy of our flagship Opportunities EIS Fund.
Learn more

Meet the Parkwalk team

Combining our diverse range of skills and experience with integrity and transparency the Parkwalk team has an outstanding track record for supporting high-growth innovation that delivers returns.

Cassie Doherty
Amy Virdee
Becky Amankwah
Meet the team

Empowering Innovation

Parkwalk Funds invest in dynamic university spin-out companies seeking to commercialise intellectual property and technology. From investing in seed to later stage companies, we help fantastic management teams develop and build world-class successful businesses.

SERG Technologies

SERG Technologies is developing a connected platform which enables remote, patient-specific assessment of all Parkinson’s disease motor symptoms, delivering actionable insights that optimise treatment, promote lifestyle changes thus increasing patient mobility and independence.

Surrey NanoSystems

Surrey NanoSystems has developed technologies that deliver precise, ordered nanomaterial structures for advanced CMOS manufacturing processes at low temperatures. Using this technology, the Company developed super-black coatings, including Vantablack®. Vantablack® is revolutionary in its ability to be applied to light-weight, temperature-sensitive structures, whilst absorbing 99.96% of incident

Definigen

DefiniGEN provides human cells to the life science and drug discovery sectors for use in lead optimization and toxicity programmes. DefiniGEN’s proprietary production platform OptiDIFF robustly generates human cell types including liver hepatocytes using hIPSC human Induced Pluripotent Stem Cell technology.

View Portfolio